Pharmaceutical

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio

UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.

Jun 27, 2023 - 20:00
Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio
UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.
Read the original article

Tags:

Previous Article

Pfizer takes on haemophilia B gene therapy market with new FDA application

Next Article

Wane in Covid demand hurts Walgreens as profits drop to $118m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

UK negotiates reform for branded drug payment amidst industry dissatisfaction

UK negotiates reform for branded drug payment amidst in...

May 6, 2023

STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud

STAT+: Pharmalittle: Bristol Myers to buy schizophrenia...

Dec 23, 2023

Comparison of Humira biosimilars in the US and Europe

Comparison of Humira biosimilars in the US and Europe

Mar 25, 2023